Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
InspireMD ( (NSPR) ) just unveiled an announcement.
On June 23, 2025, InspireMD announced that the FDA granted premarket approval for its CGuard Prime Carotid Stent System in the United States, marking a significant milestone for the company. The approval, supported by the C-GUARDIANS pivotal trial, positions InspireMD to launch the stent system in the U.S. market, potentially impacting the carotid stenting industry by offering a less invasive treatment option for carotid artery disease.
The most recent analyst rating on (NSPR) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.
Spark’s Take on NSPR Stock
According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.
InspireMD faces significant challenges with profitability and cash flow, negatively impacting its financial performance and valuation. Technical indicators suggest bearish momentum, but recent corporate developments and potential market opportunities provide some optimism. Overall, the stock is currently under pressure, with strategic improvements needed to enhance its outlook.
To see Spark’s full report on NSPR stock, click here.
More about InspireMD
InspireMD, Inc. operates in the medical device industry, focusing on the development of advanced stent systems for carotid artery disease. Their primary product, the CGuard Prime Carotid Stent System, is designed to prevent strokes by providing sustained embolic protection through its novel mesh-covered design.
Average Trading Volume: 48,893
Technical Sentiment Signal: Sell
Current Market Cap: $75.36M
See more insights into NSPR stock on TipRanks’ Stock Analysis page.